21202-79-9

Upstream product

• 611-35-8 4-chloroquinoline 
• 347335-64-2 4-chloro-1-formyl-2-(4-methoxy)phenyl-2H-quinoline 
• 3813-92-1 2-(4-methoxyphenyl)-1,4-dihydro-4-oxoquinoline 
• 5720-07-0 4-methoxyphenylboronic acid 
• 703-61-7 2,4-dichloroquinoline 
• 21286-73-7 4-hydroxy-2-(4-methoxyphenyl)quinoline 
• 100-07-2 4-methoxy-benzoyl chloride 
• 551-93-9 2-aminoacetophenone 
• 33768-41-1 N-(2-acetyl-phenyl)-4-methoxy-benzamide 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 100-06-1 1-(4-methoxyphenyl)ethanone 

Downstream Products

• 510755-70-1 N-(4-methoxyphenyl)-2-[4-methoxyphenyl]quinolin-4-amine 
• 1099705-57-3 N,N-diethyl-2-(4-methoxyphenyl)quinolin-4-amine 
• 1099705-55-1 2-(4-methoxyphenyl)-N,N-dimethylquinolin-4-amine 
• 1246760-57-5 3-(2-(4-methoxyphenyl)quinolin-4-ylamino)propan-1-ol 
• 1447235-55-3 4-(4-fluorophenyl)-2-(4-methoxyphenyl)quinoline 
• 676589-32-5 2,4-bis(4-methoxyphenyl)quinoline 

Relevant academic research and scientific papers

MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS

Pharmaceutical compositions of the invention comprise TDP-43 binding agents having a disease-modifying action in the treatment of diseases associated with TDP-43 that include ALS, FTLD, CTE, hippocampal sclerosis of aging (CARTS), Alzheimers disease, and Alzheimers disease related disorder, and disease that involve excess amounts of TDP-43 in the cytosol.

INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF

Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A).

QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS

The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and nonneoplastic diseases.

Synthesis of 2,4-diarylquinolines: Nickel-catalysed ligand-free cross-couplings of 4-chloro-2-arylquinolines with arylmagnesium halides in 2-methyltetrahydrofuran

A ligand-free and room temperature protocol for the synthesis of 2,4-diarylquinolines is described. Treatment of 4-chloro-2-arylquinolines with arylmagnesium halides in the presence of a catalytic amount of nickel(II) chloride without ligands in 2-methylt

Synthesis and evaluation of graveoline and graveolinine derivatives with potent anti-angiogenesis activities

A series of graveoline and graveolinine derivatives were synthesized. The biological results showed that most of graveoline derivatives possessed higher cytotoxicity and better inhibitive effect against the adhesion and migration of human umbilical vein e

Investigation of amination in 4-chloro-2-phenylquinoline derivatives with amide solvents

Novel 4-amino-2-phenylquinoline derivatives were synthesized by reacting various 4-chloro-2-arylquinoline compounds having activated chloro group with the corresponding amide solvents at reflux for overnight. The activity of amination by the amide solvent

A novel one-pot oxidative deformylation of N-formyldihydroquinolines employing ferric chloride hexahydrate. Synthesis of 4-chloro-2-phenylquinolines and 4-chloro-2-(1,3-diphenyl-1H-pyrazol-4-yl)quinolines

(Chemical Equation Presented) A novel versatile one-pot oxidative deformylation approach has been developed to synthesize 4-chloro-2- phenylquinolines and 4-chloro-2-(1,3-diphenyl-1H-pyrazol-4-yl)quinolines from the corresponding N-formyldihydroquinolines

4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists

Screening of the Roche compound library led to the identification of 4-aminoquinoline 4 as structurally novel NR1/2B subtype selective NMDA receptor antagonist. The SAR which was developed in this series resulted in the discovery of highly potent and in vivo active blockers.